The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic Driven Non-Small Cell Lung Cancer: A University of California Lung Cancer Consortium Retrospective Study
Published in JTO Clinical and Research Reports, 2022
In this paper, survival models with propensity score are fitted and compared to analyze the cancer data.
Recommended citation: Benjamin, David J., Shuai Chen, Joanna B. Eldredge, Shiruyeh Schokrpur, Debory Li, Zhikuan Quan, Jason W. Chan et al. "The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study." JTO Clinical and Research Reports 3, no. 12 (2022): 100427.